New androgen-receptor-targeting drugs, such as enzalutamide, provide a substantial survival benefit for patients with castration-resistant prostate cancer, but treatment resistance has been reported. In this Perspectives article, Claessens and colleagues describe the mechanisms underlying the development of such resistance and discuss their clinical relevance.
- Frank Claessens
- Christine Helsen
- Steven Joniau
